Showing results (1-10 of 526) with videos related to

Sort By:
Pageof 53
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|May 31, 2024
A Public Option for Clinical Trials? Lessons from Convalescent PlasmaVictor Roy, Joseph S Ross, Reshma Ramachandran
Journal of Pharmaceutical Policy and Practice|March 4, 2024
Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016-2019 dataOmar Qureshi, Reshma Ramachandran, Joseph S Ross
JAMA Health Forum|June 20, 2025
Public Health Implications of Legal Challenges to the FDA's Regulation of Laboratory-Developed TestsKushal T Kadakia, Joseph S Ross, Reshma Ramachandran
Health Affairs Scholar|January 15, 2026
Changes in pharmaceutical industry payments to physicians after New Jersey's 2018 restrictionNeeraj G Patel, Reshma Ramachandran, Joseph S Ross
BMJ Open|January 23, 2023
Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a cross-sectional studyMaryam Mooghali, Laura Glick, Reshma Ramachandran, et al.
Journal of General Internal Medicine|January 27, 2026
Polypharmacy Among US Older Adults with Limited English Proficiency: 2013-2018Yimei Wan, Reshma Ramachandran, K Jane Muir, et al.
JAMA Health Forum|April 17, 2026
US Food and Drug Administration Sentinel Initiative and Postmarket Drug Safety Surveillance: A ReviewErfan Taherifard, Joseph S Ross, Reshma Ramachandran, et al.
Clinical Trials (London, England)|October 15, 2025
Confirmatory evidence supporting single pivotal trial new drug approvals by the Food and Drug Administration, 2015 through 2023Carla Barile Godoy, Reshma Ramachandran, Pradyumna Sapre, et al.
Journal of General Internal Medicine|December 22, 2025
Level of Evidence and Strength of Recommendations in US Medical Society Clinical Practice Guidelines, 2019-2023: A Cross-Sectional AnalysisOmar Qureshi, Joseph S Ross, Reshma Ramachandran, et al.
JAMA Network Open|August 27, 2024
Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough TherapiesMaryam Mooghali, Joshua D Wallach, Joseph S Ross, et al.
Pageof 53